News for 'CEXI' - (CDEX CEO Provides an Updated Management Briefing; Dr. Wade Poteet Transitions From Principal Scientist to Project Consultant)
TUCSON, AZ, Mar 23, 2009 (MARKET WIRE via COMTEX) -- CDEX Inc. (OTCBB: CEXI)
announces that effective April 1, 2009, Dr. Wade Poteet will step down from his
position as Principal Scientist and become a project consultant supporting CDEX
on an as needed basis. Dr. Poteet, the Company's 1QFY0910Q and other subjects
are discussed by CEO Malcolm Philips in the "CEO Corner" of our website at
www.cdexinc.com.
"As CDEX overcame the scientific hurdles associated with our product lines, two
years ago we agreed that I would transition to a support role for the company
allowing me more time to pursue other interests," said Dr. Wade Poteet. "In
January 2008 I started the transition by reducing my work schedule and, after
passing my 65th birthday, will now complete the transition by going to a project
based consulting role with the company. I am very proud of the progress of the
entire CDEX Team over the past seven years in taking a technology from a dream
to where we have two very good product lines making differences in peoples'
lives today. Those at CDEX are very much like family and I wish them well in the
future."
"Dr. Poteet is one of the founding leaders of CDEX," said Malcolm Philips,
founding CDEX CEO. "He has been very instrumental in moving the CDEX technology
to a mature science that forms the basis for expansion of our current product
lines and development of new applications. Wade combines a strong scientific
mind with practical hands-on development, and is rounded out by his outside
interests, including being a grandfather, rancher, member of his Church Choir,
bible study leader and musician who has played over 2820 gigs in the Tucson
area. It is that unique and humble personality that will be sorely missed in the
office. We wish Wade well and know that we will continue to see him frequently."
About CDEX
CDEX develops, manufactures and globally distributes products to the healthcare
and security markets. The ValiMed(TM) product line provides life-saving
validation of high-risk medications and returned narcotics. The ID2(TM) product
line detects trace amounts of illegal drugs, such as methamphetamine. CDEX
expects to advance its patented technologies to serve additional markets. To
meet its plans, CDEX must strengthen its financial position as stated
periodically in its SEC filings. For more information, contact Malcolm Philips
at mphilips@cdex-inc.com.
AI
